radiopharmaceutical

DNA blood test improves patient selection for radiopharmaceutical therapy in prostate cancer

A noninvasive DNA blood test can identify metastatic castration-resistant prostate cancer (mCRPC) patients who are most likely to benefit from 223Ra radiopharmaceutical therapy and monitor their progress throughout treatment, according to new research published in the July issue of The Journal of Nuclear Medicine. Incorporating this new approach to DNA profiling into clinical practice has the potential […]

Read More

FAP-targeted radiopharmaceutical therapy shows broad effectiveness across multiple cancers

A novel radiopharmaceutical therapy approach that targets fibroblast activation protein (FAP)—which is highly expressed on many types of cancers—is safe and effective for patients, according to a new study published in the June issue of The Journal of Nuclear Medicine. In a study of nearly 90 patients with 21 different types of cancer, FAP-targeted radiopharmaceutical therapy […]

Read More